Extinction of West Nile Virus by Favipiravir Through Lethal Mutagenesis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2017 Aug 30

PMID 28848019

Citations 40

Authors

Estela Escribano-Romero

Nereida Jimenez de Oya

Esteban Domingo

Juan Carlos Saiz

Affiliations

Soon will be listed here.

Abstract

Favipiravir is an antiviral agent effective against several RNA viruses. The drug has been shown to protect mice against experimental infection with a lethal dose of West Nile virus (WNV), a mosquito-borne flavivirus responsible for outbreaks of meningitis and encephalitis for which no antiviral therapy has been licensed; however, the mechanism of action of the drug is still not well understood. Here, we describe the potent antiviral activity of favipiravir against WNV, showing that it decreases virus-specific infectivity and drives the virus to extinction. Two passages of WNV in the presence of 1 mM favipiravir-a concentration that is more than 10-fold lower than its 50% cytotoxic concentration (CC)-resulted in a significant increase in mutation frequency in the mutant spectrum and in a bias toward A→G and G→A transitions relative to the population passaged in the absence of the drug. These data, together with the fact that the drug is already licensed in Japan against influenza virus and in a clinical trial against Ebola virus, point to favipiravir as a promising antiviral agent to fight medically relevant flaviviral infections, such as that caused by WNV.

Citing Articles

A Comprehensive Review of the Development and Therapeutic Use of Antivirals in Flavivirus Infection.

Tripathi A, Chauhan S, Khasa R Viruses. 2025; 17(1).

PMID: 39861863 PMC: 11769230. DOI: 10.3390/v17010074.

Pharmacogenomic Studies of Antiviral Drug Favipiravir.

Shumyantseva V, Bulko T, Chistov A, Kolesanova E, Agafonova L Pharmaceutics. 2024; 16(4).

PMID: 38675164 PMC: 11053860. DOI: 10.3390/pharmaceutics16040503.

An equine iPSC-based phenotypic screening platform identifies pro- and anti-viral molecules against West Nile virus.

Cochet M, Piumi F, Gorna K, Berry N, Gonzalez G, Danckaert A Vet Res. 2024; 55(1):32.

PMID: 38493182 PMC: 10943879. DOI: 10.1186/s13567-024-01290-1.

Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development.

Kim D, Lai C, Cha I, Jung J Viruses. 2024; 16(1).

PMID: 38257828 PMC: 10818334. DOI: 10.3390/v16010128.

Favipiravir Analogues as Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase, Combined Quantum Chemical Modeling, Quantitative Structure-Property Relationship, and Molecular Docking Study.

Latosinska M, Latosinska J Molecules. 2024; 29(2).

PMID: 38257352 PMC: 10818557. DOI: 10.3390/molecules29020441.

References

Blazquez A, Saiz J . West Nile virus (WNV) transmission routes in the murine model: intrauterine, by breastfeeding and after cannibal ingestion. Virus Res. 2010; 151(2):240-3. DOI: 10.1016/j.virusres.2010.04.009. View

Day C, Smee D, Julander J, Yamshchikov V, Sidwell R, Morrey J . Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res. 2005; 67(1):38-45. DOI: 10.1016/j.antiviral.2005.04.002. View

Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M . Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. 2014; 69(10):2770-84. DOI: 10.1093/jac/dku209. View

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee D, Barnard D . T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009; 82(3):95-102. PMC: 7127082. DOI: 10.1016/j.antiviral.2009.02.198. View

Scharton D, Bailey K, Vest Z, Westover J, Kumaki Y, van Wettere A . Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res. 2014; 104:84-92. PMC: 3975078. DOI: 10.1016/j.antiviral.2014.01.016. View

Gowen B, Westover J, Sefing E, Van Wettere A, Bailey K, Wandersee L . Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antiviral Res. 2017; 145:131-135. PMC: 5580092. DOI: 10.1016/j.antiviral.2017.07.019. View

Gowen B, Wong M, Jung K, Smee D, Morrey J, Furuta Y . Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res. 2009; 86(2):121-7. PMC: 3008316. DOI: 10.1016/j.antiviral.2009.10.015. View

Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A . Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 2015; 213(8):1253-61. PMC: 4799667. DOI: 10.1093/infdis/jiv586. View

Morrey J, Taro B, Siddharthan V, Wang H, Smee D, Christensen A . Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 2008; 80(3):377-9. PMC: 2587511. DOI: 10.1016/j.antiviral.2008.07.009. View

10.

de Avila A, Moreno E, Perales C, Domingo E . Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. Virus Res. 2017; 233:105-112. DOI: 10.1016/j.virusres.2017.03.014. View

11.

Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi V, Gillemot S, Andrei G . Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis. Antimicrob Agents Chemother. 2016; 60(11):6679-6691. PMC: 5075073. DOI: 10.1128/AAC.01156-16. View

12.

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K . Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005; 49(3):981-6. PMC: 549233. DOI: 10.1128/AAC.49.3.981-986.2005. View

13.

Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S . Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014; 105:17-21. DOI: 10.1016/j.antiviral.2014.02.014. View

14.

Perales C, Iranzo J, Manrubia S, Domingo E . The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol. 2012; 20(12):595-603. DOI: 10.1016/j.tim.2012.08.010. View

15.

Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K . In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46(4):977-81. PMC: 127093. DOI: 10.1128/AAC.46.4.977-981.2002. View

16.

Caroline A, Powell D, Bethel L, Oury T, Reed D, Hartman A . Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Negl Trop Dis. 2014; 8(4):e2790. PMC: 3983105. DOI: 10.1371/journal.pntd.0002790. View

17.

Arias A, Thorne L, Goodfellow I . Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife. 2014; 3:e03679. PMC: 4204012. DOI: 10.7554/eLife.03679. View

18.

Merino-Ramos T, Blazquez A, Escribano-Romero E, Canas-Arranz R, Sobrino F, Saiz J . Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus. PLoS One. 2014; 9(9):e108056. PMC: 4168257. DOI: 10.1371/journal.pone.0108056. View

19.

Zhang S, Vogt M, Oliphant T, Engle M, Bovshik E, Diamond M . Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis. 2009; 200(2):202-5. PMC: 2752978. DOI: 10.1086/599794. View

20.

Pfeiffer J, Kirkegaard K . A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A. 2003; 100(12):7289-94. PMC: 165868. DOI: 10.1073/pnas.1232294100. View